ENVB (Enveric Corp) יחס שווי שוק לשווי בספרים

Enveric Biosciences (ENVB) management is optimizing costs by shifting toward licensing its developments to preserve liquidity. The price-to-book ratio visualizes this trend, where the value 0.67 captures the metric level. The business foundation relies on the patent-protected Psybrary AI platform. The company's innovations are focused on creating modified psychedelics for depression therapy without hallucinogenic effects.

The price-to-book ratio determines the gap between an asset's price and its net assets. By analyzing the historical P/BV multiple of a company, an investor identifies either a business undervaluation or a systemic degradation of capital. This metric indicates the extent to which the market is willing to pay a premium for future earnings relative to current assets. For Enveric Biosciences (ENVB), this discount reflects expectations regarding the efficiency of its AI platform for automating neuropharmacological research. The robotization of molecule development is intended to transform book value into high market value.